Neurocrine Biosciences names new Chief Medical Officer

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a neuroscience-focused biopharmaceutical company with a market capitalization of $10.26 billion, has announced the appointment of Dr. Sanjay Keswani as Chief Medical Officer (CMO), effective June 2, 2025. Dr. Keswani, an experienced physician-scientist with over 20 years in the pharmaceutical industry, will oversee the company’s clinical development and medical affairs. According to InvestingPro analysis, the company’s stock is currently trading near its 52-week low, presenting a potential opportunity for investors interested in the biotech sector.

Dr. Keswani will take over from Dr. Eiry W. Roberts, who will transition to a strategic advisory role after seven years as CMO. During her tenure, Dr. Roberts led the expansion of indications for INGREZZA® and the development of CRENESSITY™, both of which received FDA approval.

The incoming CMO has held significant roles in the industry, including President and CEO of ImmunoBrain and Senior Vice President at Hoffman La Roche. Dr. Keswani’s experience spans large pharmaceutical firms and biotechnology startups, contributing to the development of several approved medicines. He will continue serving on the board of directors for ImmunoBrain.

Neurocrine CEO, Dr. Kyle W. Gano, praised Dr. Keswani’s strategic expertise, highlighting the expansion of the company’s therapeutic modalities. Dr. Keswani expressed enthusiasm for joining Neurocrine, citing the company’s commitment to diverse therapeutic approaches, including small molecules, peptides, antibodies, and gene therapy.

Dr. Keswani’s academic credentials include an elected Fellowship at the Royal College of Physicians, UK, and faculty status at The Johns Hopkins Hospital, where he also ran a neuroimmunology research lab.

Neurocrine Biosciences, headquartered in San Diego, is dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio features FDA-approved treatments and compounds in mid- to late-phase clinical development.

The information provided is based on a press release statement from Neurocrine Biosciences.

In other recent news, Neurocrine Biosciences announced a new $500 million share repurchase program, following the completion of a $300 million accelerated repurchase plan. This move is part of the company’s strategy to balance investment in commercial products and research and development while returning capital to shareholders. Neurocrine Biosciences also began a Phase 1 clinical trial for NBI-1140675, a novel VMAT2 inhibitor aimed at treating neurological and neuropsychiatric conditions. The trial will assess the safety and tolerability of this new compound. In terms of earnings, RBC Capital Markets recently adjusted its revenue expectations for Neurocrine Biosciences, projecting $2.585 billion in 2025, with a peak of $3.08 billion in 2028. They also reduced the stock price target from $148 to $139 due to increasing restrictions on the use of Ingrezza, a key product. Meanwhile, Neurocrine Biosciences presented promising study results for INGREZZA, showing that 59.2% of participants achieved remission of tardive dyskinesia symptoms after 48 weeks of treatment. The study, presented at the 2025 Psychiatry Update Conference, highlighted the potential long-term efficacy of INGREZZA. Additionally, Stifel analysts have adjusted their expectations for Neurocrine Biosciences’ first-quarter sales of Ingrezza, aligning with the company’s conservative outlook expressed at recent investor conferences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.